TECOVIRIMAT: A COMPREHENSIVE REVIEW OF NOVEL DRUG FOR MONKEYPOX DISEASE
DOI:
https://doi.org/10.22159/ijcpr.2023v15i5.3066Keywords:
Tecovirimat, Smallpox, Variola virus, Antiviral therapy, US-FDA, Animal ruleAbstract
Orthopoxvirus infections caused by pathogenic agents require therapeutic intervention. Animal models of orthopoxvirus disease are crucial for assessing the effectiveness of antiviral medications and determining the right dose and duration of treatment in the absence of disease-affected individuals. Antiviral drugs for the treatment of severe orthopoxvirus infections have been developed as a result of research on smallpox preparedness. Concerns for the public's health have been raised by the monkeypox virus, a new zoonotic orthopoxvirus that can infect humans and produce a serious, contagious illness. An infection with the monkeypox virus causes a systemic, febrile rash condition that resembles smallpox in many ways. Monkeypox virus is an emergent human pathogen. It can nonetheless result in severe morbidity and mortality in humans while being less deadly than smallpox. In this review, we have explored a new antiviral drug, Tecovirmat. This drug prevents the development of the extracellular enveloped virus required for cell-to-cell transmission. It acts by limiting the production of egress-competent enveloped virions, which are necessary for the virus's spread within the host, by decreasing the action of the orthopoxvirus VP37 envelope-wrapping protein. It was approved by US-FDA for the treatment of smallpox as per Animal Rule, which bases marketing approval on a product's effectiveness in pertinent animal models.
Downloads
References
European Centre for Disease Prevention and Control. Factsheet Health Prof on Monkeypox. Available from: https://www.ecdc.europa.eu/en/all-topics-z/monkeypox/factsheet-health-professionals#:~:text=The%20pathogen,%2Drelated%20poxviruses%20%5B2%5D. [Last accessed on 21 Sep 2022]
Merchlinsky M, Albright A, Olson V, Schiltz H, Merkeley T, Hughes C. The development and approval of tecoviromat (TPOXX®), the first antiviral against smallpox. Antiviral Res. 2019 Aug;168:168-74. doi: 10.1016/j.antiviral.2019.06.005, PMID 31181284.
Choudhary G, Prabha PK, Gupta S, Prakash A, Medhi B. Monkeypox infection: a quick glance. Indian J Pharmacol. 2022;54(3):161-4. doi: 10.4103/ijp.ijp_400_22, PMID 35848685.
Grosenbach DW, Honeychurch K, Rose EA, Chinsangaram J, Frimm A, Maiti B. Oral tecovirimat for the treatment of smallpox. N Engl J Med. 2018 Jul 5;379(1):44-53. doi: 10.1056/NEJMoa1705688, PMID 29972742.
Smith SK, Self J, Weiss S, Carroll D, Braden Z, Regnery RL. Effective antiviral treatment of systemic orthopoxvirus disease: ST-246 treatment of prairie dogs infected with monkeypox virus. J Virol. 2011 Sep;85(17):9176-87. doi: 10.1128/JVI.02173-10, PMID 21697474.
O’Laughlin K, Tobolowsky FA, Elmor R, Overton R, O’Connor SM, Damon IK. Clinical use of tecovirimat (Tpoxx) for treatment of monkeypox under an investigational new drug protocol–United States, May-Aug 2022. MMWR Morb Mortal Wkly Rep. 2022 Sep 16;71(37):1190-5. doi: 10.15585/mmwr.mm7137e1, PMID 36107794.
Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR. The changing epidemiology of human monkeypox-a potential threat? A systematic review. PLOS Negl Trop Dis. 2022 Feb 11;16(2):e0010141. doi: 10.1371/journal.pntd.0010141, PMID 35148313.
Macneil A, Reynolds MG, Braden Z, Carroll DS, Bostik V, Karem K. Transmission of atypical varicella-zoster virus infections involving palm and sole manifestations in an area with monkeypox endemicity. Clin Infect Dis. 2009 Jan 1;48(1):e6-8. doi: 10.1086/595552, PMID 19025497.
World Health Organization (WHO). WHO director-general declares the ongoing monkeypox outbreak a Public Health Emergency of International Concern. Available from: https://www.who.Int/Europe/news/item/23-07-2022-who-director-general-declares-the-ongoing-monkeypox-outbreak-a-public-health-event-of-international-concern. [Last accessed on 21 Sep 2022]
Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, Rippen S. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J Virol. 2005 Oct;79(20):13139-49. doi: 10.1128/JVI.79.20.13139-13149.2005, PMID 16189015.
Jordan R, Leeds JM, Tyavanagimatt S, Hruby DE. Development of ST-246® for treatment of poxvirus infections. Viruses. 2010 Nov;2(11):2409-35. doi: 10.3390/v2112409, PMID 21994624.
Grosenbach DW, Honeychurch K, Rose EA, Chinsangaram J, Frimm A, Maiti B. Oral tecovirimat for the treatment of smallpox. N Engl J Med. 2018 Jul 5;379(1):44-53. doi: 10.1056/NEJMoa1705688, PMID 29972742.
Smith GL, Vanderplasschen A, Law M. The formation and function of extracellular enveloped vaccinia virus. J Gen Virol. 2002;83(12):2915-31. doi: 10.1099/0022-1317-83-12-2915, PMID 12466468.
Siegrist EA, Sassine J. Antivirals with activity against Mpox: a clinically oriented review. Clin Infect Dis. 2023;76(1):155-64. doi: 10.1093/cid/ciac622. PMID 35904001.
Hoy SM. Tecovirimat: first global approval. Drugs. 2018;78(13):1377-82. doi: 10.1007/s40265-018-0967-6, PMID 30120738.
SIGA Technologies Inc. TPOXX (tecovirimat) capsules for oral use: US prescribing information. 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208627s000lbl.pdf. [Last accessed on 21 Nov 2022]
Leeds JM, Fenneteau F, Gosselin NH, Mouksassi MS, Kassir N, Marier JF. Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST-246 to protect against smallpox in humans. Antimicrob Agents Chemother. 2013 Mar;57(3):1136-43. doi: 10.1128/AAC.00959-12, PMID 23254433.
National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the care and use of laboratory animals. 8th ed. Washington, (DC): National Academies Press. US; 2011. Available from: https://www.ncbi.nlm.nih.gov/books/NBK54050/. doi: 10.17226/12910.
Russo AT, Grosenbach DW, Chinsangaram J, Honeychurch KM, Long PG, Lovejoy C. An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications. Expert Rev Anti Infect Ther. 2021 Mar;19(3):331-44. doi: 10.1080/14787210.2020.1819791, PMID 32882158.
Quenelle DC, Buller RM, Parker S, Keith KA, Hruby DE, Jordan R. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents Chemother. 2007 Feb;51(2):689-95. doi: 10.1128/AAC.00879-06, PMID 17116683.
Jordan R, Goff A, Frimm A, Corrado ML, Hensley LE, Byrd CM. ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob Agents Chemother. 2009 May;53(5):1817-22. doi: 10.1128/AAC.01596-08, PMID 19223621.
Mucker EM, Goff AJ, Shamblin JD, Grosenbach DW, Damon IK, Mehal JM. Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (Smallpox). Antimicrob Agents Chemother. 2013 Dec;57(12):6246-53. doi: 10.1128/AAC.00977-13, PMID 24100494.
Nalca A, Hatkin JM, Garza NL, Nichols DK, Norris SW, Hruby DE. Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antiviral Res. 2008 Aug;79(2):121-7. doi: 10.1016/j.antiviral.2008.03.005, PMID 18479761.
Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, Rippen S. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J Virol. 2005 Oct;79(20):13139-49. doi: 10.1128/JVI.79.20.13139-13149.2005, PMID 16189015.
Russo AT, Grosenbach DW, Brasel TL, Baker RO, Cawthon AG, Reynolds E. Effects of treatment delay on efficacy of tecovirimat following lethal aerosol monkeypox virus challenge in cynomolgus macaques. J Infect Dis. 2018 Sep 22;218(9):1490-9. doi: 10.1093/infdis/jiy326, PMID 29982575.
Matias WR, Koshy JM, Nagami EH, Kovac V, Moeng LR, Shenoy ES. Tecovirimat for the treatment of human monkeypox: an initial series from Massachusetts, United States. Open Forum Infect Dis. 2022 Jul 27;9(8):ofac377. doi: 10.1093/ofid/ofac377, PMID 35949403.
Sherwat A, Brooks JT, Birnkrant D, Kim P. Tecovirimat and the treatment of monkeypox–past, present, and future considerations. N Engl J Med. 2022;387(7):579-81. doi: 10.1056/NEJMp2210125, PMID 35921403.
Jordan R, Leeds JM, Tyavanagimatt S, Hruby DE. Development of ST-246® for treatment of poxvirus infections. Viruses. 2010;2(11):2409-35. doi: 10.3390/v2112409, PMID 21994624.
Siga Human Bioarmor. Home page internet POXX® (tecovirimat). Corvallis, OR: SIGA Technologies, Inc; 2018. Available from: https://www.siga.com/wp-content/themes/sigahba/TPOXX-Fact-Sheet.pdf. [Last accessed on 21 Nov 2022]
Jordan R, Tien D, Bolken TC, Jones KF, Tyavanagimatt SR, Strasser J. Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antimicrob Agents Chemother. 2008 May;52(5):1721-7. doi: 10.1128/AAC.01303-07, PMID 18316519.
Jordan R, Chinsangaram J, Bolken TC, Tyavanagimatt SR, Tien D, Jones KF. Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. Antimicrob Agents Chemother. 2010 Jun;54(6):2560-6. doi: 10.1128/AAC.01689-09, PMID 20385870.
Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, Leeds JM, Bolken TC, Jones KF. Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 d in human volunteers. Antimicrob Agents Chemother. 2012 Sep;56(9):4900-5. doi: 10.1128/AAC.00904-12, PMID 22777041.
Desai AN, Thompson GR, Neumeister SM, Arutyunova AM, Trigg K, Cohen SH. Compassionate use of tecovirimat for the treatment of monkeypox infection. JAMA. 2022;328(13):1348-50. doi: 10.1001/jama.2022.15336, PMID 35994281.
Grosenbach DW, Honeychurch K, Rose EA, Chinsangaram J, Frimm A, Maiti B. Oral tecovirimat for the treatment of smallpox. N Engl J Med. 2018 Jul 5;379(1):44-53. doi: 10.1056/NEJMoa1705688, PMID 29972742.
Published
How to Cite
Issue
Section
Copyright (c) 2023 AJAY KUMAR SHUKLA, SAURAV MISRA
This work is licensed under a Creative Commons Attribution 4.0 International License.
